News

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Fresh Money for a Chlamydia Vaccine Using Synthetic Biology

 

Date: 11/08/2015


Prokarium Ltd today announced a new £377k (€534k) funding from SynbiCITE to develop an innovative Chlamydia vaccine using synthetic biology. The new therapy could help the 92 million people affected by Chlamydia each year and help fighting one of the most common sexually transmitted infections.

The £498k (€706k) Chlamydia vaccine project is funded at £377k (€534k) from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology, and £121k (€172k) from Prokarium and will enable Prokarium and its collaborator Prof Robin Shattock of Imperial College to complete the pre-clinical development of the vaccine which could enter clinical trials in 2017.

For more click here

Source: Labiotech

© Catalyst Innovation Portal 2019